Loxo Partners with Merus on Bispecific Antibody Therapies
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 1 (Table of Contents)
Published: 23 Jan-2021
DOI: 10.3833/pdr.v2021.i1.2586 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Loxo Oncology at Lilly has agreed to partner with Merus to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies based on its Biclonics® platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS